Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
|Articles|May 23, 2012
GOP Mixed on Health Moves
Advertisement
Congressional Republicans are divided over what to do if the Supreme Court strikes down all or part of the health-care overhaul next month.
House Republican freshmen from moderate districts say they need to have credible alternatives to present to their constituents if the court—or lawmakers—eliminate the law. They are eager to find ways to replicate popular provisions of the law, such as those requiring coverage for people with pre-existing conditions and allowing young adults to stay on their parents' insurance plans until age 26.
Read the full story:
Source: The Wall Street Journal
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
IL-23 inhibitor risankizumab outperforms TYK2 inhibitor deucravacitinib for PASI 90 in biologic-naive moderate plaque psoriasis.
Dupilumab cut hand eczema severity (59.8% vs 15.2% with placebo), regardless of a patient's atopic history.
Christos Vaklavas, MD, discussed barriers limiting rural oncology access and challenges to adopting resource-intensive therapies.
FDA cut required monitoring for tarlatamab’s first 2 doses from 22-24 hours to 6-8 hours, easing a barrier to community cancer care.
Shiven B. Patel, MD, MBA, shares strategies for closing biomarker testing gaps, including among patients with non–small cell lung cancer.
The ESC's 2026 heart failure guidelines overhaul HF classification, rename therapy categories, and add a new HFpEF recommendation.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Risankizumab Outperforms Deucravacitinib in Moderate Plaque Psoriasis
5